MedTrace Logo

MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy

NCT00180271 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1820

Last updated 2018-12-19

Study results available
· View outcomes & findings →

Summary

The MADIT-CRT trial is designed to determine if combined implantable cardiac defibrillator (ICD)-cardiac resynchronization therapy (CRT-D) will reduce the risk of mortality and heart failure (HF) events by approximately 25%, in subjects who are in New York Heart Association (NYHA) functional Class II with non-ischemic or ischemic cardiomyopathy and subjects who are in NYHA functional Class I with ischemic cardiomyopathy, left ventricular dysfunction (ejection fraction \[EF\] \< or = 0.30), and prolonged intraventricular conduction (QRS duration \> or = 130 ms).

Conditions

  • Tachycardia
  • Congestive Heart Failure

Interventions

DEVICE

Cardiac resynchronization therapy with defibrillation

Boston Scientific Corporation Market Released Cardiac Resynchronization therapy with defibrillation

DEVICE

Implantable Cardioverter Defibrillator (ICD)

Boston Scientific Corporation Market Released Implantable Cardioverter Defibrillator

Sponsors & Collaborators

  • University of Rochester

    collaborator OTHER

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Arthur J Moss, MD · University of Rochester, NY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2009-06-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00180271 on ClinicalTrials.gov